Introduction to ACOT8 (G10005)

Target Name: ACOT8

NCBI ID: G10005

ACOT8

Introduction to ACOT8

ACOT8 is an essential enzyme involved in lipid metabolism which has gained attention as a promising drug target and biomarker for various diseases. This article aims to provide a comprehensive overview of ACOT8, its physiological role, its relevance in disease pathogenesis, and its potential as a therapeutic target or biomarker.

1. The Role of ACOT8 in Lipid Metabolism:
ACOT8, short for Acyl-CoA thioesterase 8, is a member of the thioesterase protein family. It is primarily expressed in tissues involved in lipid metabolism, such as liver, adipose tissue, and skeletal muscle. The main function of ACOT8 is to catalyze the hydrolysis of fatty acyl-CoAs into free fatty acids and CoA, thus regulating the concentration of active fatty acids in the cell. This process is crucial for maintaining lipid homeostasis and energy balance.

2. ACOT8 in Disease Pathogenesis:
2.1 Obesity and Metabolic Syndrome:
Dysregulation of lipid metabolism is a common feature of obesity and metabolic syndrome. Several studies have shown that ACOT8 expression is significantly altered in these conditions. Higher expression levels of ACOT8 have been observed in adipose tissue of obese individuals, indicating increased fatty acid mobilization and storage. Moreover, genetic variations in the ACOT8 gene have been associated with increased risk of developing metabolic disorders.

2.2 Non-Alcoholic Fatty Liver Disease (NAFLD):
NAFLD, characterized by excessive fat accumulation in the liver, is closely linked to abnormal lipid metabolism. ACOT8 has been identified as a potential mediator in NAFLD pathogenesis. Studies using animal models have demonstrated that ACOT8 deficiency exacerbates hepatic steatosis by impairing fatty acid degradation. Conversely, upregulating ACOT8 expression or activity could potentially alleviate NAFLD by promoting fatty acid oxidation.

2.3 Cancer:
Emerging evidence suggests a role for ACOT8 in cancer development and progression. Increased ACOT8 expression has been observed in various cancer types, including breast, lung, and colorectal cancer. ACOT8 promotes cancer cell survival and growth by enhancing lipid metabolism and supporting the synthesis of biomolecules necessary for proliferation. Additionally, ACOT8 has been implicated in drug resistance, making it an attractive target for cancer therapy.

3. Therapeutic Potential of ACOT8:
ACOT8 has emerged as an attractive therapeutic target for several diseases, including obesity, metabolic disorders, NAFLD, and cancer. Modulating ACOT8 activity could potentially normalize lipid metabolism and restore cellular homeostasis. Several approaches have been explored to target ACOT8, including small molecule inhibitors, RNA interference, and gene editing technologies. However, more research is needed to fully understand the complex regulation of ACOT8 and its precise therapeutic implications.

4. ACOT8 as a Biomarker:
4.1 Metabolic Disorders:
Given its association with metabolic disorders, ACOT8 has the potential to serve as a diagnostic or prognostic biomarker. Monitoring ACOT8 expression levels in relevant tissues or through non-invasive means, such as blood tests or imaging techniques, can provide insights into disease progression and therapeutic response.

4.2 Cancer:
ACOT8 expression could provide valuable information about tumor aggressiveness and treatment response. High ACOT8 expression may indicate poor prognosis or resistance to therapy, whereas its downregulation could suggest a more favorable outcome. Utilizing ACOT8 as a biomarker could aid in early detection, personalized treatment decisions, and monitoring disease recurrence.

Conclusion:
ACOT8, a key player in lipid metabolism, holds immense potential as a therapeutic target and biomarker for various diseases. Targeting ACOT8 could provide novel strategies for developing therapies against obesity, metabolic disorders, NAFLD, and cancer. Additionally, monitoring ACOT8 expression levels could aid in disease diagnosis, prognosis, and treatment response assessment. Further research and clinical studies are required to fully unravel the therapeutic and biomarker potential of ACOT8.

Protein Name: Acyl-CoA Thioesterase 8

Functions: Catalyzes the hydrolysis of acyl-CoAs into free fatty acids and coenzyme A (CoASH), regulating their respective intracellular levels (PubMed:9299485, PubMed:9153233, PubMed:15194431). Displays no strong substrate specificity with respect to the carboxylic acid moiety of Acyl-CoAs (By similarity). Hydrolyzes medium length (C2 to C20) straight-chain, saturated and unsaturated acyl-CoAS but is inactive towards substrates with longer aliphatic chains (PubMed:9299485, PubMed:9153233). Moreover, it catalyzes the hydrolysis of CoA esters of bile acids, such as choloyl-CoA and chenodeoxycholoyl-CoA and competes with bile acid CoA:amino acid N-acyltransferase (BAAT) (By similarity). Is also able to hydrolyze CoA esters of dicarboxylic acids (By similarity). It is involved in the metabolic regulation of peroxisome proliferation (PubMed:15194431)

The "ACOT8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACOT8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets